Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Monisha Sivakumar
Institution:
Prelude Therapeutics Incorporated (United States)
Observed institutions:
Texas A&M Health Science Center,
Prelude Therapeutics Incorporated (United States),
Texas A&M University
ORCID:
0009-0002-8937-4289
Observed ORCID:
0009-0002-8937-4289
OpenAlex ID:
A5017032244
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
2023
·
Jack Carter
, Michael Hulse
, et al.
·
Cancer Research Communications
·
43
PDF
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
2025
·
Michael Hulse
, Min Wang
, et al.
·
Cancer Research
·
31
Extracellular Vesicles in Premature Aging and Diseases in Adulthood Due to Developmental Exposures
2021
·
Marisa R Pinson
, Dae D Chung
, et al.
·
Aging and Disease
·
15
PDF
Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader
2022
·
Michael Hulse
, Anjana Agarwal
, et al.
·
Cancer Research
·
11
Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells
2021
·
Koichi Ito
, Venkat Thodima
, et al.
·
Cancer Research
·
8
Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2
2024
·
Artem Shvartsbart
, Koichi Ito
, et al.
·
Cancer Research
·
4
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
2023
·
Koichi Ito
, Michael Hulse
, et al.
·
Molecular Cancer Therapeutics
·
4
Abstract 2159: PRMT5 inhibitor PRT543 displays potent antitumor activity in U2AF1S34F and RBM10LOF spliceosome-mutant non-small cell lung cancer in vitro and in vivo
2022
·
Jack Carter
, Koichi Ito
, et al.
·
Cancer Research
·
3
Abstract 5793: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile
2026
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
2025
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Discovery of Tetrasubstituted Quinazolin-4(3 H )-ones as Wild-type-sparing, Highly Selective PI3KαH1047R Inhibitors
2026
·
Chun Chen
, Ryan Holmes
, et al.
·
Journal of Medicinal Chemistry
Figure S10 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S11 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S7 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S3 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S8 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Show more works
View as search
Works count:
51
Citation count:
123
H-index:
5
I10-index:
4
Year
Topic
Type